Electronic patient diaries in clinical research



Similar documents
Your Go-to COPD Guide

Outcome of Drug Counseling of Outpatients in Chronic Obstructive Pulmonary Disease Clinic at Thawangpha Hospital

Idiopathic Pulmonary Fibrosis

PLAN OF ACTION FOR. Physician Name Signature License Date

Agenda. ARITHMOS Presents: Introduction to epro. EDC and epro integration General Overview. epro and ecrf Integration: a case study

1 ALPHA-1. What is Alpha-1? A family history... of lung disease? of liver disease? FOUNDATION

Management of exacerbations in chronic obstructive pulmonary disease in Primary Care

Prevention of Acute COPD exacerbations

COPD - Education for Patients and Carers Integrated Care Pathway

Documenting & Coding. Chronic Obstructive Pulmonary Disease (COPD) Presented by: David S. Brigner, MLA, CPC

Medication and Devices for Chronic Obstructive Pulmonary Disease (COPD)

Using Patient Reported Outcome as Primary or Key Secondary Endpoints-A Regulatory Perspective

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

1 ALPHA-1. Am I an Alpha-1 Carrier? FOUNDATION FOUNDATION. Learn how being an Alpha-1 carrier can affect you and your family

1 ALPHA-1. The Liver and Alpha-1 Antitrypsin Deficiency (Alpha-1) FOUNDATION FOUNDATION. A patient s guide to Alpha-1 liver disease

Role of eclinical Systems in FDA Regulated Studies. Jonathan S. Helfgott

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Guideline for Industry

The Value of A Qualified Outcome Measure Janet Woodcock, M.D.

Session 8: Bring Your Own Device (BYOD) - Application in Clinical Trials

COPD and Asthma Differential Diagnosis

Objectives COPD. Chronic Obstructive Pulmonary Disease (COPD) 4/19/2011

Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims

Mobile Medical Application Development: FDA Regulation

What Lies Ahead? Trends to Watch: Health Care Product Development in North America

James F. Kravec, M.D., F.A.C.P

The Liver and Alpha-1. Antitrypsin Deficiency (Alpha-1) 1 ALPHA-1 FOUNDATION

Hospital to Physician Office to Home: A Respiratory Led Program Across the Continuum of Care

Data Management and Good Clinical Practice Patrick Murphy, Research Informatics, Family Health International

PCOM Letterhead [Substitute same from participating institution and, of course, change Department, PI, and Co-Investigators]

Monitoring Clinical Trials with a SAS Risk-Based Approach

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE. Current Step 4 version

Marilyn Borkgren-Okonek, APN, CCNS, RN, MS Suburban Lung Associates, S.C. Elk Grove Village, IL

Quit & Get Fit! Frequently Asked Questions For Personal Trainers (November 2011)

Longitudinal Modeling of Lung Function in Respiratory Drug Development

SLEEP DISTURBANCE AND PSYCHIATRIC DISORDERS

ASK A DOC. Clinical Trial Update May 28, Welcome!

EUROPEAN LUNG FOUNDATION

EU PAS Register Guide

COPD PROTOCOL CELLO. Leiden

The impact of FDA and EMA guidances regarding Patient Reported Outcomes (PRO) on the drug development and approval process

An Overview of Asthma - Diagnosis and Treatment

Guidance for Industry

University of Hawai i Human Studies Program. Guidelines for Developing a Clinical Research Protocol

Exploratory data: COPD and blood eosinophils. David Price: am

Bronchodilators in COPD

Better Breathing with COPD

epro Integration with Oracle Remote Data Capture

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

Measure Information Form (MIF) #275, adapted for quality measurement in Medicare Accountable Care Organizations

COPD It Can Take Your Breath Away

Sponsor Novartis Pharmaceuticals

Inhaler Technique Check

Respiratory Clinical Trial Services. the difference is clear. Your respiratory clinical trials partner

Wireless Remote Monitoring System for ASTHMA Attack Detection and Classification

Coventry Health Care of Florida, Inc. Coventry Health Plan of Florida, Inc. Coventry Health and Life Insurance Company Commercial Lines of Business

3/11/15. COPD Disease Management Tackling the Transition. Objectives. Describe the multidisciplinary approach to inpatient care for COPD patients

NEW RESPIRATORY HEALTH PROGRAM

TravelCare Medical Questionnaire Instruction Sheet for Agents

ST. MICHAEL S HOSPITAL Guidelines for Reporting Serious Adverse Events / Unanticipated Problems to the SMH Research Ethics Board (REB) July 09, 2014

Compare the physiologic responses of the respiratory system to emphysema, chronic bronchitis, and asthma

Quality Management in Clinical Trials

CMS National Coverage Policy

Using Social Media in Research: Regulatory and IRB Considerations

Medicare Pulmonary Rehabilitation (PR) Benefit Frequently Asked Questions June 2010 (Latest Updates: December 18, 2013 and February 12, 2014)

Guidance for Industry

ASTHMA IN INFANTS AND YOUNG CHILDREN

Licensed Healthcare Providers Guidelines for Telemedicine Using the MyDocNow Platform

BEACON HEALTH STRATEGIES, LLC TELEHEALTH PROGRAM SPECIFICATION

ROLE OF THE RESEARCH COORDINATOR

Medicare Part A. Pulmonary Rehab Program Services Web-Based Training February 25, Q & As

GENERAL INFORMATION. Adverse Event (AE) Definition (ICH GUIDELINES E6 FOR GCP 1.2):

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE CONDUCT OF POST-MARKETING SURVEILLANCE STUDIES OF VETERINARY MEDICINAL PRODUCTS

Efficient Asset Tracking: From Manual to Automated

Telehealth Solutions Enhance Health Outcomes and Reduce Healthcare Costs

J of Evolution of Med and Dent Sci/ eissn , pissn / Vol. 3/ Issue 65/Nov 27, 2014 Page 13575

Welcome to the training on the TransCelerate approach to Risk-Based Monitoring. This course will take you through five modules of information to

EVALUATION OF AUTOMATIC CLASS III DESIGNATION FOR STUDIO on the Cloud Data Management Software DECISION SUMMARY

Principal Investigator and Sub Investigator Responsibilities

Supplement to the Guidance for Electronic Data Capture in Clinical Trials

Frequently Asked Questions about Crab Asthma

Chronic Obstructive Pulmonary Disease (COPD) Programme

Development of Case Report Forms

Disease Management Identifications and Stratification Health Risk Assessment Level 1: Level 2: Level 3: Stratification

Subject: No. Page PROTOCOL AND CASE REPORT FORM DEVELOPMENT AND REVIEW Standard Operating Procedure

COPD. Information brochure for chronic obstructive pulmonary disease.

Transcription:

Topics Electronic diaries in Clinical Trials Electronic diaries versus Paper Electronic patient diaries in clinical research Case Study: Novel detection of exacerbations of COPD with patient reported outcome (EXACT-PRO) and Blackberry Isabella Montagna Annamaria Muraro Electronic diaries compliance with regulations Good Clinical Data Management Practices Case study: Forward, CHIESI Farmaceutici The EXACT-PRO questionnaire on BlackBerry Electronic data flow Electronic diaries improvement in study Detection of ECOPD with EXACT-PRO and BlackBerry Conclusions 2

Electronic diaries Electronic diaries Subjects diaries are essential in clinical trials that assess occurrence and intensity of symptoms, effects of medication, perceived quality of life. Scientific research has consistently demonstrated that paper diaries make difficult for subjects to comply with the protocol. Otherwise electronic diaries ensure undeniable advantages. By capturing data directly from patients at home, they solve problems often experienced by using paper diaries. What electronic diaries do (and paper diaries don t) Record date and time for each entry automatically Prevent to skip mandatory information Allow to enter only formatted responses Remind automatically to complete Transfer data directly to a central database Make real-time data available to all More pharmaceutical companies worldwide replace paper diaries with electronic ones. 3 4

Electronic diaries vs paper Electronic diaries vs paper Electronic diaries Pros Reliable, real time data Reduced missing data Reduced data entry errors High diaries compliance and possibility to monitor it Real time access to study and patient data Integration with clinical databases Cons Training required Familiarity with technology More startup resources needed Paper diaries Pros Established medium Fewer startup resources No training required Easy to produce Cons No reliable date/time stamping (retrospective data entry) Poor quality of data (incomplete, unreadable information, inappropriate responses) Lack of compliance 5 6

Electronic diaries compliance with regulations FDA draft Guidance for industry: Electronic Source documentation in Clinical Investigations (January 2011). EMA Expectations from Electronic Source Data and Data Transcribed To Electronic Data Collection Tools in Clinical Trials (September 2010). FDA Guidance for industry: Patient Reported Outcome measures: Use in in Medical Product Development to support Labeling Claims (December 2009). CDISC Leveraging the CDISC standard to facilitate the use of electronic source data within clinical trials (November 2006). US 21 CFR Part 11 Electronic records, electronic signatures (1997) Electronic Diaries - Good Clinical Data Management Practices Electronic diaries collect Patient Reported Outcome to quantify symptoms, disability, emotional states, responses to treatment, Questionnaires are often developed to measure PRO and to quantify the results by established algorithms. Best Practices for epro Use standard, validated questionnaires. Provide detailed instructions to subjects for completion of the electronic diary and conduct appropriate training. Ensure electronic systems are proper validated in compliance with US 21 CFR Part 11. Ensure all processes are in place to assure compliance with regulatory requirements regardind protection and ownership of electronic data. Ensure appropriare level of network security and infrastructure. 7 8

Case Study: Forward, CHIESI Farmaceutici Case Study: Forward, CHIESI Farmaceutici Forward is a Clinical Study sponsored by Chiesi Farmaceutici aimed at demonstrating that Foster, a drug registered to cure a severe respiratory pathology called asthma, can be also used to effectively cure another respiratory disease called Chronic Obstructive Pulmonary Disease (COPD). More than 1000 patients involved from 18 countries and treated for 48 weeks. The Clinical Study must satisfy all regulatory authorities and legislation requirements, reaching an effective symptoms control that can be obtained only with a day-by-day report from patients about their health status and frequent visits to the medical centres. To comply with protocol requirements, Chiesi Farmaceutici adopted the solution of electronic diaries. Blackberries were identified as the best technological platform to host the EXACT-PRO questionnaire. 9 10

The EXACT-PRO questionnaire The EXACT-PRO questionnaire The EXAcerbations of Chronic Pulmonary Disease Tool (EXACT) is a patient-reported outcome (PRO) measure designed to standardize the method for evaluating the frequency, severity, and duration of acute exacerbations of COPD and chronic bronchitis (AECB) in international studies and clinical trials. The EXACT is a 14-item daily diary to be completed by the patient on the device each evening before bedtime, taking less than 3 minutes to complete. Chiesi customized EXACT-PRO with 4 study specific additional questions. 14 questions Total score - 0 to 100 (higher scores = more severe health status) Domain scores - Scoring 0 to 100 (higher scores = more severe symptoms) - Breathlessness (5 Items) - Cough and Sputum (2 Items) - Chest Symptoms (3 Items) 4 custom questions to record information on rescue medication and study treatment intake. 11 12

EXACT-PRO on BlackBerry EXACT-PRO on BlackBerry The electronic diary on BlackBerry was given to each patient for recording: Daily symptoms and patient status Use of recue medication Compliance of study medication intake. The patients were instructed on how to use the device. Mean patients age: 64 years To facilitate patients in approaching technology, the following measurements were adopted: the clinical study application is the ONLY application to which the users have access only one question per page is displayed. To achieve compliance with the protocol, the following settings were applied: each question must be answered and edited by patients patients can edit today s diary only notifications remind patients to fill in the questionnaire. BlackBerry is one of the most user-friendly device. 13 14

EXACT-PRO on BlackBerry EXACT-PRO on BlackBerry To comply with privacy requirements: patients remain anonymous to Chiesi who only gets data about questionnaire tracking BlackBerry PIN communications are encrypted no data are stored on the device but information are immediately transmitted to the central database and synchronized in a secure Web portal. No need for telephone line (only mobile signal required). Patients health is always controlled by notifications automatically sent to patients and investigators. Notifications to the patients Global (automatically scheduled and delivered) Individual (in case of symptoms worsening) Please remember to call your doctor if your symptoms worsen. Notifications to the investigators Variation in patient s symptoms will trigger an alert that will be sent by e-mail or by text. 15 16

Electronic diaries data flow Electronic diaries compliance Subjects Diary Database Diary Web Portal BlackBerries compliance during treatment period EXACT-PRO ALERT Investigator ALERT 100.00 90.00 80.00 70.00 60.00 50.00 40.00 30.00 20.00 10.00 0.00 CHIESI Clinical database Compliance = total days recorded in the BB / total days expected * 100 Mean compliance = 88.64% 17 18

Detection of ECOPD with EXACT-PRO and BlackBerry Detection of ECOPD with EXACT-PRO and BlackBerry Electronic diaries but not only +12 pt Threshold Exacerbations of COPD are estimated from persistent increase in daily symptoms that require treatment with systemic steroids, antibiotics and/or hospitalization/er visit. CHIESI Farmaceutici employs electronic diaries on BlackBerry to automatically detect possible ECOPD. A baseline score is set in the device to identify the patient s stable condition. Baseline score = value calculated during the 14 days run-in period when patients are treated with their maintenance therapy. Baseline 1 event as per the EXACT-PRO detection definition Any variation in score of at least 12 points for two consecutives day is considered as significant worsening of the patient s status. 19 20

Detection of ECOPD with EXACT-PRO and BlackBerry Conclusions Electronic diaries improvement in studies More precise data as they are collected daily. Real-time data available both to investigators and sponsor. Daily monitoring of patients health. Daily monitoring of patients compliance in BlackBerry usage and in study medication intake. A - The EXACT-PRO detection threshold matches the diagnosed ECOPD. B - Patient s condition worsens according to symptoms recorded in the BB but no subsequent treatment until further worsening triggering treatment. C - No clear worsening recorded in the BB but patient receives treatment for ECOPD. Corrective actions immediately in place to correct lack of compliance: additional training to patient BlackBerry replacement in case of device malfunction. Savings in questionnaires collections (automatic data transfer to the clinical database) and analysis Savings in the visits with doctors. 21 22